[go: up one dir, main page]

ES2524251T3 - Proteínas de tipo interferón humano recombinantes - Google Patents

Proteínas de tipo interferón humano recombinantes Download PDF

Info

Publication number
ES2524251T3
ES2524251T3 ES07720038.4T ES07720038T ES2524251T3 ES 2524251 T3 ES2524251 T3 ES 2524251T3 ES 07720038 T ES07720038 T ES 07720038T ES 2524251 T3 ES2524251 T3 ES 2524251T3
Authority
ES
Spain
Prior art keywords
human interferon
recombinant human
type proteins
interferon type
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07720038.4T
Other languages
English (en)
Inventor
Haitao Wang
Chunsheng Mao
Jizhi Li
Ling Wang
Yong Du
Longbin Liu
Jing Xu
Rui Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novagen Holding Corp
Original Assignee
Novagen Holding Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novagen Holding Corp filed Critical Novagen Holding Corp
Application granted granted Critical
Publication of ES2524251T3 publication Critical patent/ES2524251T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)

Abstract

Un polinucleótido aislado que codifica para una proteína que tiene actividades biológicas de tipo interferón humano, seleccionándose dicho polinucleótido del grupo que consiste en polinucleótidos que comprenden cada uno una secuencia nucleotídica al menos un 95 % idéntica a la SEC ID Nº: 1, y en el que la proteína tiene una actividad anti-proliferativa al menos 10 veces mayor que el interferón humano alfa 2b (HuIFN-a2b).

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30

Claims (1)

  1. imagen1
ES07720038.4T 2007-06-18 2007-06-22 Proteínas de tipo interferón humano recombinantes Active ES2524251T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US764786 2007-06-18
US11/764,786 US7625555B2 (en) 2007-06-18 2007-06-18 Recombinant human interferon-like proteins
PCT/CA2007/001123 WO2008154719A1 (en) 2007-06-18 2007-06-22 Recombinant human interferon-like proteins

Publications (1)

Publication Number Publication Date
ES2524251T3 true ES2524251T3 (es) 2014-12-04

Family

ID=40132903

Family Applications (2)

Application Number Title Priority Date Filing Date
ES07720038.4T Active ES2524251T3 (es) 2007-06-18 2007-06-22 Proteínas de tipo interferón humano recombinantes
ES12159128.3T Active ES2586398T3 (es) 2007-06-18 2007-06-22 Proteínas de tipo interferón humano recombinantes

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES12159128.3T Active ES2586398T3 (es) 2007-06-18 2007-06-22 Proteínas de tipo interferón humano recombinantes

Country Status (21)

Country Link
US (8) US7625555B2 (es)
EP (3) EP2078082B1 (es)
JP (3) JP5439189B2 (es)
KR (2) KR20130027043A (es)
CN (3) CN102250918A (es)
AU (1) AU2007355415B2 (es)
BR (1) BRPI0716948B1 (es)
CA (1) CA2692358C (es)
DK (2) DK2078082T3 (es)
ES (2) ES2524251T3 (es)
HK (2) HK1129128A1 (es)
IL (1) IL196673A (es)
MX (1) MX2009001366A (es)
MY (1) MY167485A (es)
NZ (1) NZ574306A (es)
PL (2) PL2465935T3 (es)
PT (2) PT2078082E (es)
RU (1) RU2469091C2 (es)
TW (1) TWI375716B (es)
WO (1) WO2008154719A1 (es)
ZA (1) ZA200901680B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
PE20130557A1 (es) * 2010-03-04 2013-05-19 Pfenex Inc Metodo para producir proteinas de interferon recombinantes solubles sin desnaturalizacion
EP3572511B1 (en) * 2013-09-20 2023-07-12 National Institutes of Biomedical Innovation, Health and Nutrition Complex containing oligonucleotide having immunopotentiating activity and use thereof
LT6164B (lt) 2013-10-15 2015-06-25 Uab Biotechnologinės Farmacijos Centras "Biotechpharma" Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas
AU2015291123C1 (en) * 2014-07-14 2020-12-10 Gennova Biopharmaceuticals Limited A novel process for purification of rHu-GCSF
IL264923B1 (en) * 2016-09-01 2025-03-01 Proqr Therapeutics Ii Bv Single-stranded RNA-editing oligonucleotides with chemical modifications
JP7045322B2 (ja) * 2016-12-02 2022-03-31 三菱商事ライフサイエンス株式会社 リボース含有酵母調味料
US10780931B2 (en) * 2018-05-21 2020-09-22 Ronald Siwicki Kickstand assembly
CN109627343A (zh) * 2018-12-27 2019-04-16 北京美福源生物医药科技有限公司 长效细胞因子基因衍生物融合蛋白
CN113289006A (zh) * 2020-02-24 2021-08-24 杰华生物技术(青岛)有限公司 一种重组细胞因子基因衍生蛋白或其片段的用途

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US369922A (en) 1887-09-13 Jacket for steam-cylinders
US2004200A (en) * 1931-10-02 1935-06-11 Union Switch & Signal Co Lamp socket adapter
US3699222A (en) * 1958-03-11 1972-10-17 Nat Res Dev Production of viral interfering substances
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
US4885166A (en) * 1985-06-11 1989-12-05 Ciba-Geigy Corporation Hybrid interferons
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8803365D0 (en) * 1988-02-13 1988-03-16 Ciba Geigy Ag Antiviral combination
US5705363A (en) * 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
PT730470E (pt) * 1993-11-10 2002-08-30 Enzon Inc Conjugados melhorados de interferao-polimero
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6335160B1 (en) * 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
FR2741892B1 (fr) * 1995-12-04 1998-02-13 Pasteur Merieux Serums Vacc Procede de preparation d'une banque multicombinatoire de vecteurs d'expression de genes d'anticorps, banque et systemes d'expression d'anticorps "coliclonaux" obtenus
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
AU761577C (en) * 1997-12-08 2004-02-05 Genentech Inc. Human interferon-epsilon: a type I interferon
US6685933B1 (en) * 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
US6514729B1 (en) * 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7431921B2 (en) * 1999-08-27 2008-10-07 Maxygen Aps Interferon beta-like molecules
AU6687000A (en) 1999-08-27 2001-03-26 Maxygen Aps New interferon beta-like molecules
US20040002474A1 (en) * 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
EP1238082A2 (en) 1999-10-07 2002-09-11 Maxygen, Inc. Ifn-alpha homologues
PL356007A1 (en) 1999-11-12 2004-05-31 Maxygen Holdings Ltd Interferon gamma conjugates
IT1317835B1 (it) * 2000-02-15 2003-07-15 San Raffaele Centro Fond Citochine modificate per uso nella terapia del cancro.
WO2001072993A1 (fr) 2000-03-31 2001-10-04 Mochida Pharmaceutical Co., Ltd. Inhibiteur de liaison entre le recepteur de type toll et cd14
EP1334128A2 (en) 2000-11-02 2003-08-13 Maxygen Aps New multimeric interferon beta polypeptides
JP2004537964A (ja) 2000-11-03 2004-12-24 ペストカ バイオメディカル ラボラトリーズ インコーポレイテッド インターフェロン、それに関する使用及び組成物
YU48703A (sh) 2001-02-27 2006-05-25 Maxygen Aps Novi interferonu beta-slični molekuli
KR20030094336A (ko) 2001-04-06 2003-12-11 맥시겐 홀딩스 엘티디 인터페론 감마 폴리펩티드 변이체
US7038015B2 (en) * 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
US6958388B2 (en) * 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
FR2825102B1 (fr) * 2001-05-23 2003-08-29 Genodyssee Nouveaux polynucleotides et polypeptides de l'interferon alpha 14
WO2003002152A2 (en) 2001-06-29 2003-01-09 Maxygen Aps Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins
CN1431018A (zh) 2002-01-10 2003-07-23 北京东康龙病毒生物技术工程研究中心 抗HSV感染和镇痛的人甲硫氨酸脑啡肽干扰素α－m融合蛋白制剂
KR20040104504A (ko) 2002-03-12 2004-12-10 맥시겐 에이피에스 스트로크의 치료를 위한 인터페론 베타-유사 분자
EP1539814A2 (en) 2002-07-03 2005-06-15 Maxygen Holdings Ltd. c/o Close Brothers (Cayman) Limited Full-length interferon gamma polypeptide variants
AU2003254641A1 (en) 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
AU2003263552A1 (en) * 2002-09-09 2004-03-29 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
AU2003297285A1 (en) 2002-11-18 2004-06-15 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
TW200509961A (en) * 2003-05-23 2005-03-16 Pestka Biomedical Lab Inc Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections
BRPI0511196A (pt) * 2004-05-19 2007-12-04 Maxygen Inc polipeptìdeo isolado ou recombinante, conjugado, composição, célula hospedeira, vetor, métodos para preparar um polipeptìdeo, para preparar um conjugado, para reduzir o número de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna hcv, dna hbv e rna hiv no soro de um paciente infectado com hcv, hbv e hiv, e, uso do polipeptìdeo, do conjugado ou da composição
JP2008513356A (ja) 2004-08-09 2008-05-01 アリオス バイオファーマ インク． 合成高度糖鎖付加プロテアーゼ耐性ポリペプチド変異体、それを使用する経口製剤および方法
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs
JP2008545393A (ja) * 2005-05-18 2008-12-18 マキシジェン， インコーポレイテッド 進歩したインターフェロンαポリペプチド
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins

Also Published As

Publication number Publication date
US7867482B2 (en) 2011-01-11
US7625555B2 (en) 2009-12-01
CN103483443A (zh) 2014-01-01
NZ574306A (en) 2012-07-27
HK1129128A1 (en) 2009-11-20
US20170015723A1 (en) 2017-01-19
ZA200901680B (en) 2010-03-31
TWI375716B (en) 2012-11-01
BRPI0716948B1 (pt) 2022-04-05
EP2078082A1 (en) 2009-07-15
US8425895B2 (en) 2013-04-23
US20080312148A1 (en) 2008-12-18
MY167485A (en) 2018-08-30
DK2078082T3 (en) 2014-12-01
AU2007355415B2 (en) 2012-07-26
CN102250918A (zh) 2011-11-23
MX2009001366A (es) 2009-04-17
WO2008154719A1 (en) 2008-12-24
IL196673A0 (en) 2011-08-01
KR20130027043A (ko) 2013-03-14
PT2078082E (pt) 2014-11-27
JP5439189B2 (ja) 2014-03-12
KR20100033468A (ko) 2010-03-30
JP2016117753A (ja) 2016-06-30
IL196673A (en) 2015-08-31
PL2465935T3 (pl) 2017-08-31
US9234022B2 (en) 2016-01-12
KR101384307B1 (ko) 2014-05-21
DK2465935T3 (en) 2016-08-22
BRPI0716948A2 (pt) 2013-02-19
CA2692358A1 (en) 2008-12-24
US20100129904A1 (en) 2010-05-27
US10538565B2 (en) 2020-01-21
RU2009104749A (ru) 2010-11-20
EP2078082B1 (en) 2014-08-20
HK1171048A1 (zh) 2013-03-15
EP2078082A4 (en) 2009-12-16
EP2465935A2 (en) 2012-06-20
AU2007355415A1 (en) 2008-12-24
PT2465935T (pt) 2016-08-05
CA2692358C (en) 2012-11-20
CN101432428A (zh) 2009-05-13
JP2014036657A (ja) 2014-02-27
RU2469091C2 (ru) 2012-12-10
EP2465935A3 (en) 2012-08-15
US9982028B2 (en) 2018-05-29
ES2586398T3 (es) 2016-10-14
JP2010515466A (ja) 2010-05-13
US20130189226A1 (en) 2013-07-25
US20200369741A1 (en) 2020-11-26
EP2465935B1 (en) 2016-05-18
US7868151B2 (en) 2011-01-11
US20190077843A1 (en) 2019-03-14
EP3133161A1 (en) 2017-02-22
JP6099095B2 (ja) 2017-03-22
CN101432428B (zh) 2013-06-19
US20100099612A1 (en) 2010-04-22
TW200900504A (en) 2009-01-01
US20100303759A1 (en) 2010-12-02
PL2078082T3 (pl) 2015-02-27

Similar Documents

Publication Publication Date Title
ES2524251T3 (es) Proteínas de tipo interferón humano recombinantes
ES2619322T3 (es) Agente inductor de inmunidad
ES2565060T3 (es) Polipéptidos que tienen actividad de glucoamilasa y polinucleótidos que codifican los mismos
ES2531391T3 (es) Delta-5 desaturasas y procedimiento para la preparación de ácidos grasos poliinsaturados en organismos transgénicos no humanos
EA201792651A1 (ru) Аденовирусные полинуклеотиды и полипептиды
DE602005020121D1 (de) Aus wt1 stammende krebsantigenpeptide
ES2545457T3 (es) Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
AR109680A1 (es) Proteínas recombinantes y sus usos
ES2531290T3 (es) Transferasas y oxidorreductasas, ácidos nucleicos que las codifican y métodos para prepararlas y usarlas
ATE529442T1 (de) Verbesserte humane interferon-moleküle und ihre verwendungen
AR049177A1 (es) Polipeptidos y conjugados de interferon-alfa
AR072159A1 (es) Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad
AR092076A1 (es) Proteinas homodimericas
ATE553124T1 (de) Oxyntomodulinanaloga und ihre wirkungen auf das fressverhalten
ES2489715T3 (es) Procedimiento para la produccíón de colágeno humano de tipo II
BRPI0509023A (pt) nitrila hidratase de rhodococcus
ES2662325T3 (es) Inductor de respuesta inmune
AR110748A1 (es) Proteínas toxinas pesticidas activas contra insectos lepidópteros
CL2017003097A1 (es) Composiciones y métodos para el tratamiento de la enfermedad celiaca
ES2545614T3 (es) Proteínas truncadas con nudo de cistina
RS51325B (sr) Polipeptidi koji imaju antimikrobno dejstvo i polinukleotidi koji ih kodiraju
ES2534752T3 (es) Nuevo péptido antigénico contra el cáncer y utilización del mismo
ES2536238T3 (es) Péptidos antimicrobianos
AR071534A1 (es) Peptidos aislados que tienen actividad inhibitoria de la fosfolipasa
AR103586A1 (es) Proteínas quiméricas que mejoran la actividad de los dominios de unión a adn y factores de transcripción en plantas